LifeMD, Inc.
NASDAQ:LFMDMedical - Pharmaceuticals
-$0.16 today
- Market cap
- $82.17M
- Beta
- 1.99
- P/E (TTM)
- -13.8
- EPS (TTM)
- -$0.34
Volume 0.80M
Average 1.04M
LFMD Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
LifeMD, Inc.NASDAQ: LFMD
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $121.21K fell 95.5% year over year, behind the -25.4% change in trailing-twelve-month research & development. Sequentially, it fell 93.3% from the prior quarter. Over 3 fiscal years it compounded at +35.2% a year.
Context
- Research & development amounted to 3.8% of revenue in FY2025, down 0.7 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -95.5% toward the trailing-twelve-month pace of -25.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 7.35M USD
- Year-over-year change
- -22.8%
- 4-year CAGR
- +66.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.35M | -22.8% |
| FY2024 | 2024-12-31 | 9.51M | +57.0% |
| FY2023 | 2023-12-31 | 6.06M | +104.0% |
| FY2022 | 2022-12-31 | 2.97M | +213.3% |
| FY2021 | 2021-12-31 | 948.16K | — |
Research & Development vs competitors
How LFMD compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -25.4% is the 8th highest of 9, against a peer median of -10.7%.
- Research & development amounts to 3.4% of revenue for LFMD, versus a peer median of 16.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $65.65M USD | +7.6% | +0.8% | 29.5% | |
| LTM Mar 2026 | $39.88M USD | +24.6% | +1.7% | 11.5% | |
| LTM Mar 2026 | $32.9M USD | -13.4% | -7.3% | 80.8% | |
| LTM Mar 2026 | $13.97M USD | -23.1% | -7.7% | 24.2% | |
| LTM Mar 2026 | $12.72M USD | -28.5% | -13.9% | 16.0% | |
| LTM Mar 2026 | $11.7M USD | +10.5% | +3.8% | 19.8% | |
| LTM Mar 2026 | $7.53M USD | -25.4% | +35.2% | 3.4% | |
| LTM Mar 2026 | $5.08M USD | -13.4% | +14.6% | 4.7% | |
| LTM Mar 2026 | $2.25M USD | -8.0% | -34.3% | 5.4% | |
| LTM Apr 2026 | CA$0 CAD | — | — | 0.0% | |
| Peer median (excluding LFMD) | — | -10.7% | -3.3% | 16.0% | |
Competitors are the stored peer set for LFMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 92.88M | 119.03M | 152.55M | 212.45M | 194.06M |
| Cost of Revenue | 18M | 18.67M | 18.9M | 24.07M | 39.29M |
| Gross Profit | 74.88M | 100.37M | 133.65M | 188.39M | 154.76M |
| Gross Margin | 80.6% | 84.3% | 87.6% | 88.7% | 79.8% |
| Research & Development | 948.16K | 2.97M | 6.06M | 9.51M | 7.35M |
| Selling, General & Admin | 122.08M | 125.33M | 128.15M | 175.68M | 144.01M |
| Operating Expenses | 129.18M | 143.81M | 148.14M | 204.53M | 162.43M |
| Depreciation & Amortization | 355.87K | 1.09M | 6.6M | 9.49M | 7.31M |
| EBITDA | (57.94M) | (38.6M) | (8.21M) | (6.65M) | (1.52M) |
| EBITDA Margin | -62.4% | -32.4% | -5.4% | -3.1% | -0.8% |
| Operating Income | (54.3M) | (43.45M) | (14.49M) | (16.14M) | (7.67M) |
| Operating Margin | -58.5% | -36.5% | -9.5% | -7.6% | -4.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 3.02M | 1.28M | 2.6M | 2.18M | 1.36M |
| Other Income / Expenses | (7.02M) | (1.21M) | (2.92M) | (2.18M) | (2.52M) |
| Income Before Tax | (61.32M) | (44.66M) | (17.41M) | (18.33M) | (10.19M) |
| Pre-Tax Margin | -66.0% | -37.5% | -11.4% | -8.6% | -5.2% |
| Income Tax Expense | 7.7K | 360.7K | 428K | 402K | 45.72K |
| Net Income | (60.9M) | (45.54M) | (20.6M) | (18.88M) | (7.11M) |
| Net Margin | -65.6% | -38.3% | -13.5% | -8.9% | -3.7% |
| EPS (Basic) | (2.27) | (1.57) | (0.70) | (0.53) | (0.23) |
| EPS (Diluted) | (2.27) | (1.57) | (0.70) | (0.53) | (0.23) |
| Weighted Avg Shares | 27.01M | 30.98M | 33.91M | 41.2M | 45.13M |
| Weighted Avg Shares (Diluted) | 27.01M | 30.98M | 33.91M | 41.2M | 45.13M |
LifeMD, Inc.
NASDAQ:LFMD
Intrinsic Alpha fair value
Locked
Current Price
$1.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.